Morgan Stanley reiterates Overweight on Navan as accelerating signed GBV and raised guidance reinforce its growth thesis.

Overview

This earnings review argues that Navan's modest shortfall against elevated buy-side expectations does not alter the central growth thesis. Morgan Stanley highlights record forward demand indicators, faster adoption of payments and subscription products, and increased FY27 guidance as support for its reiterated Overweight and Top Pick view.

Core views

Navan reported a solid F2Q27 result, although the revenue surprise was slightly below elevated buy-side expectations. Q2 GBV was $3.0 billion, up 45% year on year versus consensus growth of 38%, while total revenue increased 35% year on year versus 28% consensus. The reported revenue beat was 6%, compared with approximately 7% expected by buy-side investors. Morgan Stanley nevertheless views the result as thesis-supportive because the FY27 revenue-growth outlook was raised from 30% to 32%, a larger organic improvement than the quarterly beat even after accounting for the BoomPop acquisition. The report's main evidence for a durable growth path is its forward-demand data. New signed GBV reached a quarterly record, 30% above any prior quarter. Trailing-12-month new signed GBV was $4.0 billion, up 60% year on year, compared with $11.0 billion of trailing-12-month overall GBV; this indicates an acceleration from approximately 50% growth in 4Q26 and 1Q27. RFP activity grew more than 200% year on year in 1H27 and win rates increased. Morgan Stanley interprets these measures as leading indicators that Navan can sustain mid-30s organic growth in FY27 and continue gaining market share. Cross-selling is another pillar of the thesis. Subscription revenue growth accelerated to 36% year on year from 26% in Q1, while payment revenue growth accelerated to 34% from 29%. The report attributes this to more customers adopting Navan's payments and expense products, supported by a less-constrained post-IPO balance sheet and a more proactive salesforce. Morgan Stanley seeks further evidence of this cross-sell into the installed base as a medium-term source of upside to estimates. Valuation underpins the positive stance. Navan traded at roughly 4x CY27 sales and 6x CY27 gross profit, while the unchanged $33 target implies 7x CY27 sales and approximately 9x–10x CY27 gross profit, below Samsara's cited 10x sales and 12x gross-profit multiples. Morgan Stanley's base case assumes about 19% revenue CAGR through CY34, $3.1 billion of revenue, a 23% operating margin and $623 million of FCF. It applies a 22x terminal-year FCF multiple and discounts at an 11.8% WACC to derive the $33 target. The bull case assumes 21% CAGR through CY34, $3.7 billion of revenue, a 22% operating margin and $703 million of FCF. A 25x terminal FCF multiple and the same 11.8% WACC yield a $46 valuation, which Morgan Stanley characterizes as a 5:1 risk/reward skew. The bear case assumes about 17% CAGR, $2.4 billion of revenue, a 21% operating margin and $460 million of FCF; a 12x terminal FCF multiple produces a $17 bear-case value. The report identifies slower business-travel spending, poor execution and increasing competition as downside risks, while stronger supplier contracts, enterprise-customer acquisition, cross-selling and travel inflation could create upside.

Analysis framework

Morgan Stanley compares quarterly GBV, revenue and profitability with consensus and buy-side expectations, then evaluates forward indicators such as signed GBV, RFP activity and win rates. It links cross-sell trends to longer-term growth assumptions and values Navan using scenario-based terminal free-cash-flow multiples discounted at an 11.8% WACC, supplemented by sales and gross-profit multiple comparisons with Samsara.

Methodology notes

• Valuation methodsFCFF/FCFE Free Cash Flow

  Scenario-based free-cash-flow valuation using terminal-year FCF multiples discounted at WACC.

  Morgan Stanley forecasts long-term revenue, margins and FCF in base, bull and bear cases, applies terminal FCF multiples of 22x, 25x and 12x, respectively, and discounts each outcome using an 11.8% WACC.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Leading-indicator analysis using new signed GBV, RFP activity, win rates and cross-selling.

  The report treats stronger customer demand and signed booking volume as inputs that should translate into future GBV, revenue growth and operating results.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Navan Inc (NAVN.US)

  Primary covered company; record signed GBV, raised guidance and accelerating cross-selling support Morgan Stanley's Overweight and Top Pick thesis.

  Strengths

  Record signed GBV, rising RFP activity and win rates, accelerating subscription and payments growth, market-share gains and AI leadership.

  Weaknesses

  The Q2 revenue beat was slightly below elevated buy-side expectations.

  Comparison

  The $33 target implies lower CY27 sales and gross-profit multiples than cited core peer Samsara.

  Risks

  Slower business-travel spending, poor execution and increasing competition.

• Samsara

  Core comparable used in Navan's valuation comparison.

  Comparison

  Cited at 10x sales and 12x gross profit, versus Navan's target-implied approximately 7x sales and 9x–10x gross profit.

Key data

• Q2 GBV$3.0 billion; +45% YoYVersus +38% YoY consensus growth.
• Q2 revenue growth+35% YoYVersus +28% YoY consensus growth; the revenue beat was 6% versus about 7% buy-side expectations.
• FY27 revenue guidance+32% YoYRaised from +30% YoY; the guidance midpoint was $930 million versus $910 million previously.
• New signed TTM GBV$4.0 billion; +60% YoYA record quarterly level and a leading indicator versus $11.0 billion TTM overall GBV.
• Subscription and payment revenue growth+36% YoY and +34% YoYAccelerated from +26% and +29%, respectively, in Q1.
• Base-case valuation$33 target priceBased on approximately 19% CY34 revenue CAGR, $3.1 billion revenue, 23% operating margin, $623 million FCF, 22x terminal FCF and 11.8% WACC.

Impact & implications

Morgan Stanley argues that the raised FY27 outlook and accelerating forward indicators outweigh the modest earnings-expectations miss. It views cross-sell adoption and market-share gains as the mechanisms for upside to relatively conservative near-term estimates, while the current valuation remains below the cited Samsara comparison.

Risks

• Business-travel spending could slow.
• Navan could execute poorly against its growth and cross-selling plans.
• Competition could increase.
• AI disruption risk to application software and travel remains a sector overhang.

What to watch

• Whether new signed GBV, RFP activity and win rates remain strong.
• Execution of cross-selling travel, payments and spend-management products into the existing customer base.
• Supplier-contract upside and enterprise-customer acquisition.
• Trends in business-travel spending and competitive intensity.